PE20121177A1 - Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado - Google Patents
Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzadoInfo
- Publication number
- PE20121177A1 PE20121177A1 PE2012000120A PE2012000120A PE20121177A1 PE 20121177 A1 PE20121177 A1 PE 20121177A1 PE 2012000120 A PE2012000120 A PE 2012000120A PE 2012000120 A PE2012000120 A PE 2012000120A PE 20121177 A1 PE20121177 A1 PE 20121177A1
- Authority
- PE
- Peru
- Prior art keywords
- dose
- treatment
- breast cancer
- advanced breast
- fulvestrant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 238000009261 endocrine therapy Methods 0.000 abstract 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121177A1 true PE20121177A1 (es) | 2012-09-23 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000120A PE20121177A1 (es) | 2009-07-27 | 2010-07-26 | Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP2017515873A (ja) * | 2014-05-21 | 2017-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法 |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| EP3528818B1 (en) * | 2016-10-21 | 2021-09-15 | Crescita Therapeutics Inc. | Pharmaceutical compositions |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 FI FI20125207A patent/FI20125207L/fi not_active Application Discontinuation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| PE20121177A1 (es) | Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado | |
| AR061350A1 (es) | Regimen extendido de reduccion progresiva de estrogenos | |
| PA8588601A1 (es) | Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular | |
| AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| NZ745556A (en) | Androgen receptor modulator and uses thereof | |
| PE20200444A1 (es) | Terapia de combinacion para cancer de prostata | |
| CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
| MX2019014800A (es) | Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso. | |
| DOP2012000291A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| CL2009001011A1 (es) | Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa. | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| CL2020002637A1 (es) | Métodos de tratamiento de cáncer. | |
| AR091351A1 (es) | Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion | |
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| CO6430423A2 (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
| JP2013500324A5 (enExample) | ||
| MX2023005295A (es) | Tratamiento contra el cancer resistente a platino. | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| CO2024015968A2 (es) | Nuevo uso medico de la tafoxiparina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |